Background: mTORC1 is a protein kinase that plays a central role in cell growth and metabolism. Results: mTORC1 signaling activity is affected by expression levels of two apoptotic proteins, Bcl-2 and Bcl-X L . Conclusion: Bcl-2 and Bcl-X L control mTORC1 activity by affecting the binding of mTORC1 with its inhibitor FKBP38. Significance: The novel crosstalk between Bcl-2/X L and mTORC1 signaling is likely to play an important role in cancer development.
INTRODUCTION
Evasion of cell death is one of the hallmarks in cancer development (1) . Cancer cells achieve this feat by augmenting activities of various pathways that allow survival under stress conditions. One major mechanism for enhancing cell survival involves overexpression of anti-apoptotic proteins of the Bcl-2 family, such as Bcl-2 and Bcl-X L . Elevated levels of these anti-apoptotic proteins are often associated with cancer progression and contribute to the resistance of cancer cells to conventional cancer therapies (2, 3) .
Bcl-2 and Bcl-X L exert their anti-apoptotic function by binding to pro-apoptotic proteins, Bax and Bak, and thereby preventing their oligomerization on the mitochondrial membrane that leads to mitochondrial permeabilization (2) . To perform this function, the two proteins have to be recruited to mitochondria and attached to mitochondrial outermembrane through their transmembrane domain. The recruitment is achieved by association with FKBP38, a member of FK506 binding protein family that resides on mitochondria (4) . Overexpression of FKBP38 increases the levels of Bcl-2 and Bcl-X L on mitochondria and enhances resistance to apoptosis, whereas, downregulation of FKBP38 reduces the mitochondrial localized Bcl-2 and Bcl-X L , rendering cells more vulnerable to apoptosis (4, 5) .
In addition to regulating Bcl-2 and Bcl-X L function, FKBP38 also acts as an inhibitor of the mammalian target of rapamycin (mTOR), a PI-3 kinase related protein kinase (6) . mTOR controls many growth-related processes by integrating signals of various origins, including those of growth factors, nutrients, cellular energy and stresses. It exists in two distinct complexes, termed as mTOR complex 1 (mTORC1) and 2 (mTORC2) (7) . mTORC1 promotes cell growth mainly by stimulation of protein synthesis, which is achieved through phosphorylation of ribosomal S6 protein kinase (S6K) and 4E-BP1, two key factors in translation initiation (8) . mTORC2, on the other hand, acts in a distinct way. It phosphorylates Akt and enhances its pro-survival function (9) . Despite the presence of mTOR in both complexes, rapamycin, in complex with another member of the FK506 protein family, FKBP12, specifically targets mTORC1 and blocks its function. FKBP38, operating in a manner analog to that of the rapamycin-FKBP12 complex, binds to mTORC1 and prevents its activation (10) .
The association of FKBP38 with mTOR as well as with Bcl-2 and Bcl-X L is regulated by the Ras-like small GTPase Rheb in response to changes in growth factor and nutrient conditions. Upon serum or amino acid stimulation, an active Rheb binds to FKBP38 and releases Bcl-2/X L and mTORC1 from its interaction. Whereas, under serum or amino acid deprivation conditions, an inactive Rheb allows binding of FKBP38 with these proteins, which causes downregulation of mTORC1 as well as accumulation of Bcl-2/X L on mitochondria (5, 6) .
Because both mTOR and the two antiapoptotic proteins are capable of binding to FKBP38, it is possible that Bcl-2/X L and mTOR may influence each other's function by competing for FKBP38 binding. In this regard, changes in expression levels of Bcl-2/X L are expected to alter the binding of FKBP38 with mTOR and vice versa, hence affecting each other's activity. While fluctuations in expression level do not appear to be a major mechanism for mTOR regulation, they do affect dramatically the anti-apoptotic function of Bcl-2 and Bcl-X L . An increased expression of these two proteins is often associated with the resistance to apoptosis in cancer cells. Therefore, a potential regulation may occur to mTORC1 due to changes in the levels of the anti-apoptotic proteins. In this study, we examined the putative crosstalk between mTOR and the two apoptotic proteins.
EXPERIMENTAL PROCEDURES
Cell Culture and Transfection-HEK293 cells used in this study were obtained from ATCC. HEK293-myc-FKBP38 and its vector control line (HEK293-myc) were created by transfecting HEK293 cells with pcDNA3.1-3xmyc-FKBP38 or control vector and selecting clones stably expressing myc-FKBP38 at a level similar to its endogenous copy. HCT116 Bax +/+ and HCT116 Bax -/-cells were gifts from Dr. L. Zhang with permission for use from Dr. B. Vogelstein (11) . Cultured cells were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). CellTiter-Glo® Luminescent Cell Viability Assay kit from Promega was used to assay cell viability. Oxygen consumption rate (OCR) of the transfected cells was determined using XF Extracellular Flux Analyzer (Seahorse Bioscience). For amino acid starvation and repletion, cells were incubated in DMEM medium free of amino acids for 1 hr, 50x amino acid stock mixture (Sigma) or vehicle control was added to the medium to a final concentration of 1x. Cells were harvested and lysed 30 min after the addition of amino acids or vehicle control. For serum deprivation and readdition, cells were shifted to DMEM medium contain 0.2% FBS for 24 hr. FBS (Hyclone) was then added back to the medium to a final concentration of 10%. Cells were harvested and lysed upon incubation for 30 min after addition of FBS. All experiments were repeated at least three times. Representative data are shown in the figures. Antibodies and Plasmids-Antibodies for S6K, phospho-S6K(T389), S6, phospho-S6(S235/236), 4E-BP1, phospho-4E-BP1(T37/46), Bcl-X L , Mcl-1, β-actin and mTOR were purchased from Cell Signaling Technology Inc (Danvers, MA). Antibody for Bcl-2 was from Dako (Carpinteria, CA) and Bax from (Santa Cruz Biotech). Rabbit anti-FKBP38 antibody and pcDNA3.1-HA-Bcl-X L were created in our previous study (5) . pcDNA3.1-V5-Mcl-1 was kindly provided by Dr. L. Zhang. CMV-Bcl-X L -cyb5 and CMV-Bcl-X L -acta plasmids are gifts from Dr. Andrews at McMaster University (12) . Plasmid transfections were performed using Invitrogen LipofectamineTM 2000 according to manufacturer's instructions (Carlsbad, CA).
shRNA Constructs-Bcl-2 and Bcl-X L specific shRNAs were designed based on previously published RNAi sequences and cloned into pSIH-H1 shRNA expression lentivector (System Biosciences). The two Bcl-2 specific RNAi sequences are:
(Bcl-2 shRNA-1) (13); 5'-GCTGCACCTGACGCCCTTCTT -3' (Bcl-2 shRNA-2) (14) . The two Bcl-X L specific RNAi sequences are:
(Bcl-X L shRNA-2) (14) . The two Bcl-w specific RNAi sequences are:
(Bcl-w shRNA-1); 5'-TGGCAGACTTTGTAGGTTATA-3' (Bcl-w shRNA-2). The RNAi oligos were cloned into a lentiviral expression vector, pLKO.1-puro. A non-targeting shRNA control in the same vector from Addgene was used as a control. siRNA for Mcl-1 was from Santa Cruz Biotech. The FKBP38 specific shRNA construct (pLKO.1-FKBP38 shRNA) was purchased from Sigma (Clone ID TRCN 0000010595). This shRNA was used to create a HEK293 line stably expressing the construct, which reduces endogenous expression of FKBP38 by ~90%. For HEK293 and Hela cells, shRNAs were transfected with LipofectamineTM 2000 from Invitrogen. For other cell lines, shRNAs were first packed as lentiviral particles with the package system from Invitrogen and used for infecting the cells. The effects of shRNAs were analyzed 72 hr after the transfection or infection. Co-immunoprecipitation-Cultured cells at 80-90% confluence were washed with cold PBS on ice and lysed in buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1mM PMSF and 1x protease inhibitor cocktail (Roche). Lysates (5 mg) were incubated with anti-Myc antibody (9E10) linked Protein A agarose beads for 3 hr at 4°C with agitation. Beads were washed four times with lysis buffer, once with 20mM Tris-HCl (pH7.4) and boiled for 5 min in 60 μl of 2x SDS sample buffer. Samples were subjected to SDS-PAGE. Western blotting was performed by standard protocols and developed using ECL reagents (BD Biosciences). Myctagged and endogenous FKBP38 were detected with anti-FKBP38 antibody.
RESULTS
We and others have previously shown that both mTOR and anti-apoptotic proteins, Bcl-2 and Bcl-X L , are able to interact directly with FKBP38 (4-6). To test whether Bcl-2 and Bcl-X L are able to affect mTORC1 activity through binding of FKBP38, we examined the effect of Bcl-X L overexpression on mTORC1 signaling activity in HEK293 cells. As shown in Fig. 1 , we found that overexpression of Bcl-X L enhanced mTORC1-dependent phosphorylation of S6 kinase (S6K), S6 ribosomal protein (S6) and 4E-BP1 in a dose dependent manner under serum deprivation or amino acid starvation condition (Figs. 1A and 1B). Similarly, the overexpression also partially blocked dephosphorylation of S6K and 4E-BP1 induced by serum deprivation (Fig. 1C ). These observations thus confirmed that high level of Bcl-X L overexpression is able to enhance mTORC1 signaling activity. Attempt to test the effect of Bcl-2 overexpression was hindered by its toxic effect on cell growth, a phenomenon that was observed previously by other groups (16, 17) . While overexpression of Bcl-X L increased mTORC1 signaling activity, we found that overexpression of another anti-apoptotic protein, Mcl-1, had no obvious effect on the activity (Fig.  1D) .
Although Bcl-X L functions mainly on mitochondria, it also localizes to other cellular compartments, including the nucleus and ER. To determine whether the effect of Bcl-X L is mitochondrial specific, we employed mutant Bcl-X L proteins with the membrane anchor replaced either by an ER targeting sequence of cytochrome b5 (Bcl-X L -cyb5) or mitochondrial targeting sequence of ActA (Bcl-X L -acta). These two chimera proteins have been shown previously to target specifically to ER and mitochondria, respectively (12) . We found that the overexpressed mitochondrial targeted Bcl-X L retained the ability to stimulate mTORC1 activity under serum deprivation condition, but the ER targeting one lost it. Likewise, a mutant Bcl-X L without its membrane anchor (Bcl-X L ∆TM) was ineffective (Fig. 2) . These observations suggest that the ability of Bcl-X L in mTORC1 regulation depends on its mitochondrial localization.
Because overexpression of Bcl-X L enhanced mTORC1 activity, we further determined whether reduction of Bcl-2 and Bcl-X L levels had an opposite effect. Accordingly, we examined mTORC1 activity in HEK293 cells with reduced expression of Bcl-2 and Bcl-X L by specific shRNAs. As shown in Fig. 3A , we found that knockdown of Bcl-2 decreased mTORC1 dependent phosphorylation of its downstream targets. The diminished mTORC1 activity appeared to correlate with the extent of the knockdown. In cells treated with Bcl-2-shRNA-1, which reduced the level of Bcl-2 by more than 90%, we observed a drastic decrease in mTORC1 activity, while in cells treated with another shRNA (Bcl-2-shRNA-2) that was not as effective in the knockdown, we found that the downregulation in mTORC1 was moderate. Similar results were obtained when HEK293 cells were treated with Bcl-X L specific shRNAs (Fig. 3B) . Again, the effectiveness of these shRNAs on mTORC1 activity correlated with their ability in knockdown of Bcl-X L . The effect of Bcl-2 and Bcl-X L knockdown was mTORC1 specific, since we found that the activity of mTORC2, as measured by the mTORC2-dependent phosphorylation of Akt at position T473, was not changed by the knockdown (unpublished observation). To further confirm the observation from HEK293 cells, we examined the effect of Bcl-2 and Bcl-X L knockdown on mTORC1 activity in several cancer cell lines. We found that, as in HEK293 cells, knockdown of Bcl-2 or Bcl-X L reduced mTORC1activity in lung cancer line A549, breast cancer line MCF-7 and two prostate cancer lines, LNCaP and C4-2 ( Fig. 3C and unpublished  observations) . Thus, the effect of Bcl-2 and Bcl-X L knockdown on mTORC1 activity appears to be a common response.
In contrast to Bcl-2 and Bcl-X L , knockdown of two anti-apoptotic proteins, Mcl-1 and Bcl-w, did not have any effect on mTORC1 activity (Figs. 4A and 4B), suggesting that mTORC1 activity is specifically affected by the levels of Bcl-2 and Bcl-X L . Both Bcl-2 and Bcl-X L have been shown previously to interact with FKBP38 (4,5). However, we found that under the same condition at which Bcl-X L interacted with FKBP38, Bcl-w and Mcl-1 did not (Fig. 4C and unpublished  observation) . In this regard, the activity of these anti-apoptotic proteins in mTORC1 regulation appeared to correlate with their ability for binding with FKBP38.
Because the role of Bcl-2 and Bcl-X L in cell survival, it was possible that the effect on mTORC1 activity associated with Bcl-2 and Bcl-X L knockdown was caused indirectly by loss of cell viability. To test this possibility, we examined the viability of cells treated with Bcl-2 and Bcl-X L shRNAs and failed to detect a significant reduction in overall cell viability under the same growth condition at which we observed a drastic downregulation in mTORC1 activity (Fig. 5A) . We also did not detect any obvious defects in mitochondrial oxygen consumption of those treated cells (Fig. 5B) , ruling out mitochondria deregulation as a potential cause for the reduced mTORC1 activity. Furthermore, we found that mTORC1 activity was not affected in cells treated with Abt-263, a potent inhibitor of Bcl-2 (Fig.  5C ). These findings suggest that the downregulation in mTORC1 activity was not caused by reduction in cell viability. To further rule out the role of apoptosis in the effect induced by the Bcl-2 and Bcl-X L knockdown, we examined the mTORC1 activity in Bax null cells, which are resistant to apoptosis due to the absence of Bax, a major pro-apoptotic protein (11) . We found that knockdown of either Bcl-2 or Bcl-X L in the Bax null cells reduced mTORC1 activity as in the wild type control (Fig. 5D ). Taken together, these findings suggest that a reduced viability was not the cause for the downregulated mTORC1 activity in cells treated with Bcl-2 and Bcl-X L specific shRNAs.
Previous studies have shown that Bcl-2, Bcl-X L and mTOR are all able to interact with FKBP38 (5,6), which raises the possibility that Bcl-2 and Bcl-X L may affect mTORC1 activity by competing with mTOR for FKBP38 binding. In this regard, a reduced level of Bcl-2 and Bcl-X L may allow more FKBP38 to interact with mTORC1 and hence reduce its activity. To investigate this possibility, we examined the effect of Bcl-2 or Bcl-X L knockdown on mTORC1 activity in cells with FKBP38 levels reduced by a stably expressed shRNA. As shown in Fig. 6 , we found that while knockdown of Bcl-2 or Bcl-X L reduced mTORC1 activity in cells expressing a scrambled control shRNA, it failed to do so in cells expressing FKBP38 shRNA. This finding indicates that FKBP38 is involved in the Bcl-2/X L -dependent regulation of mTORC1.
We next determined whether the ability for binding with FKBP38 was essential for the effect of Bcl-X L . A previous study has shown that Bcl-2 interacts with FKBP38 through a region between its BH4 and BH3 domains (18) . Accordingly, we created a mutant Bcl-X L incapable of FKBP38 binding by deleting the corresponding region (amino acids 45 to 81) in the protein (Fig. 7) . We found that while a mitochondrial-targeted wild type Bcl-X L (Bcl-X L -acta) stimulated mTORC1 activity under serum starvation condition, the mutant Bcl-X L [Bcl-X L ∆(45-81)-acta] failed to do so (Fig. 7B ). This result suggests that the ability for FKBP38 binding is required for the effect of Bcl-X L on mTORC1. To further ascertain the role of FKBP38 in the process, we created a mutant protein containing the first 90 amino acids of Bcl-X L fused with GFP.
This mutant protein preserved the FKBP38 binding domain of Bcl-X L but lacked the BH3, BH1 and BH2 functional domains (Fig. 7A) . When expressed in cultured cells, the mutant protein (Bcl-X L -GFP-acta) was targeted to mitochondria (unpublished observation) and was able to bind with FKBP38 (Fig. 7C) . Correlating with the ability for FKBP38 binding, this mitochondrial targeted fusion protein retained the capability to stimulate mTORC1 as its wild type counterpart (Fig. 7B ). These observations demonstrate that the ability for interacting with FKBP38 but not the anti-apoptotic function is required for Bcl-X L to affect mTORC1 activity.
To further ascertain the role of FKBP38 in the Bcl-X L mediated effect, we tested whether the differences in mTORC1 activity induced by changes in Bcl-X L expression levels correlated with its association with FKBP38. In our previous study, we showed that amino acid starvation induced a strong association between mTOR and FKBP38, which led to mTORC1 downregulation (6). We hence analyzed the effect of Bcl-X L overexpression on the starvation-induced association by co-immunoprecipitation. We found that amino acid starvation increased the association in cells expressing a control vector but the effect was largely eliminated in cells expressing Bcl-X L (Fig. 8A) . Consistent with what we observed previously (6), the changes in the association of mTOR with FKBP38 correlated inversely with the mTORC1 signaling activity. In contrast, we observed an increase in the association of mTOR with FKBP38 in cells expressing a Bcl-X L shRNA in comparison with the control cells expressing a scrambled shRNA. Again, the increase was associated with a decrease in mTORC1 signaling activity (Fig. 8B) . These findings suggest that the differences in mTORC1 activity in response to changes in Bcl-2 and Bcl-X L expression levels are likely to be mediated by FKBP38.
DISCUSSION
Anti-apoptotic proteins, Bcl-2 and Bcl-X L , and mTORC1 are important factors acting synergistically at opposite sides in controlling cell proliferation. These factors are believed to be regulated independently through different mechanisms. In the present study, we find that changes in Bcl-2 and Bcl-X L expression levels affect mTORC1 signaling activity. This finding reveals the existence of a previously unknown crosstalk that renders mTORC1 signaling activity susceptible to alterations in a Bcl-2 and Bcl-X L levels. Given the fact that many cancer cells possess high levels of Bcl-2 and/or Bcl-X L , this Bcl-2/X L -dependent regulation of mTORC1 is likely to bear important implication in tumor cell survival and proliferation.
We have previously shown that Bcl-2 and Bcl-X L interact with FKBP38, an inhibitor of mTOR, which indicates that these anti-apoptotic proteins are able to compete with mTOR for FKBP38 binding (5, 6) . This competition may hence affect the amount of FKBP38 available for mTOR binding, allowing Bcl-2 and Bcl-X L to control mTORC1 activity.
Several lines of evidence support this view. First, we find that the ability of Bcl-2 and Bcl-X L to affect mTORC1 signaling correlates with their ability to interact with FKBP38. Both Bcl-2 and Bcl-X L are able to bind to FKBP38 and regulate mTORC1 activity. However, two other anti-apoptotic proteins, Bcl-w and Mcl-1, which do not bind to FKBP38 (Fig. 4C and unpublished observation) are unable to control mTORC1 (Figs. 4A and 4B ). In addition, we show that a mutant Bcl-X L containing its FKBP38 binding domain but lacking three BH domains remains active for mTORC1 stimulation (Fig. 7) , suggesting that the ability for FKBP38 binding but not the anti-apoptotic function of Bcl-X L is essential for its effect on mTORC1. Second, we find that the inhibitory effect of Bcl-2 and Bcl-X L on mTORC1 is largely abolished in cells with a downregulated FKBP38 level. Third, we demonstrate that changes in Bcl-X L levels affect the association of mTOR with FKBP38, which correlates inversely with mTORC1 signaling activity (Fig. 8) . It is hence likely that the crosstalk between the apoptotic proteins and mTORC1 is mediated by FKBP38.
The binding of Bcl-2 and Bcl-X L with FKBP38 is negatively regulated by nutrient and growth factor availability (5). It is thus expected that their competition with mTOR is at strongest when growth factor or nutrient is limited. In this regard, it is surprising that under normal growth condition, when the competition is weak, downregulation of Bcl-2 and Bcl-X L still has a remarkable impact on mTORC1 activity (Fig. 3) . This phenomenon prompted us to examine other FKBP38-independent mechanisms. Because the role of Bcl-2 and Bcl-X L in cell survival, it is possible that the inhibitory effect on mTORC1 of their knock-down is caused indirectly by reduced cell viability. However, the finding that the Bcl-2 and Bcl-X L knockdown remained effective in Bax null cells (Fig. 5D) , which are largely resistant to apoptosis, argues against this possibility. In addition, we found that inhibition of Bcl-2 and Bcl-X L apoptotic function by Abt263 inhibitor, which blocks the association of these antiapoptotic proteins with pro-apoptotic proteins (19) , had no effect on mTORC1 activity (Fig. 5C ). These observations suggest that a reduced antiapoptotic function does not contribute to the effect of Bcl-2 and Bcl-X L knockdown on mTORC1. Furthermore, we did not detect any obvious effect of the knockdown on mitochondrial function (Fig.  5B) , indicating that a compromised mitochondrial function is not a cause. Collectively, our data suggest that the effect of Bcl-2 and Bcl-X L on mTORC1 signaling activity is most likely to be mediated by FKBP38.
Overexpression of Bcl-2 and Bcl-X L is a common mechanism for cancer cells to elude apoptosis. The positive effect of Bcl-2 and X L overexpression on mTORC1 activity indicates that Bcl-2 upregulation not only enhances cell survival but also stimulates mTOR-dependent proliferation in cancer cells. In support of this notion, it was found that upregulation of Bcl-2 increased tumor cells proliferation and vascularization in prostate cancer xenografts (20) , two events under control of mTORC1. Because translation of Bcl-2 and Bcl-X L is regulated by mTOR-dependent activation of eIF4E (8), an enhanced mTORC1 activity is expected to increase the production of the two anti-apoptotic proteins, which in turn is anticipated to further stimulates mTORC1 activity through the crosstalk. As such, the crosstalk may set forth a positive feed-forward cycle that promotes survival and cell proliferation, and hence contributes to cancer progression. 
